Puma Biotechnology | PBYI - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Daiichi Sankyo JPY 2.16B 1.33B 2025-12
Esperion Therapeutics USD 22.64M 585K 2025-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 240M 15M 2026-03
Glaxosmithkline GBP 192.73M 14.79M 2026-03
Incyte USD 569K 13K 2026-03
MacroGenics USD 4.89M 1.55M 2026-03
Moderna USD 11.49B 36B 2026-03
Novartis USD 343M 39M 2026-03
Pfizer USD 671M 40M 2026-03
PTC Therapeutics USD 2.87B 2.82B 2026-03
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Takeda JPY 43.65B 79.98B 2026-03
TG Therapeutics USD 7.67M 1.13M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Vanda Pharmaceuticals -1.37B 1.97B 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12